Results 121 to 130 of about 232,812 (303)

Risk of Developing Subsequent Primary Colorectal Cancers Among Non‐Colorectal Cancer Survivors: Implications for Prevention and Screening

International Journal of Cancer, EarlyView.
ABSTRACT Cancer survivors have an elevated risk of developing subsequent primary cancers, including colorectal cancer (CRC), and may benefit from tailored screening approaches to reduce incidence and morbidity. A retrospective cohort of adults diagnosed with cancer (excluding CRC) in Alberta, Canada from 2000 to 2021 who survived at least 6 months was ...
Dylan E. O'Sullivan, Robert J. Hilsden, Hannah Harsanyi, Matthew T. Warkentin, Kareem Jamani, Huiming Yang, Darren R. Brenner, Safiya Karim, Winson Y. Cheung, Yibing Ruan   +9 more
wiley   +1 more source

Human biomarker navigator

iMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li, Qian Zhang, Zijie Wang, Zeping Gui, Jing Liu, Jingda Li, Maojun Jiang, Zukang Chang, Qingqing Han, Bendong Yang, Tariq Saeed, Jun Li, Jinghan Jia, Chenghu Song, Tong Shao, Tianhuan Peng, Xueying Zhang, Pingping Guo, Jun Luo, Gangao Yang, Yuan Wan, Gokhan Zengin, Quan Yuan, Lingru Li, Xiaohui Fan, Yang Luo, Lvyun Zhu, Yanfei Zheng, Wenjun Mao, Wenlong Sun   +29 more
wiley   +1 more source

International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

Multiple myeloma remains an incurable disease, despite the development of numerous drug classes and combinations that have contributed to improved overall survival.
International Myeloma Working Group
core  

Myeloma multiplex farmakoterápiája

, 2017
A myeloma multiplex a rosszindulatú hematológiai betegségek 10%-ért felelős. A betegség lefolyása jelentős individuális variabilitást mutat, azonban minden betegnél bekövetkezik a relapszus. Az új terápiás protokolloknak köszönhetően az 5 éves túlélésben
Törő, Imre
core  

Bisalbuminaemia in Myeloma [PDF]

Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 1985
M S, Graziani, A, Burlina
openaire   +2 more sources

Laboratory Identification of Pseudohypercalcemia Induced by Hyperglobulinemia in Multiple Myeloma: A Case Report

Journal of Clinical Laboratory Analysis, EarlyView.
Pseudohypercalcemia induced by calcium‐binding monoclonal immunoglobulin in multiple myeloma is verified via laboratory assays and validated by therapeutic response. ABSTRACT Background Pseudohypercalcemia is easily misdiagnosed in clinical practice, potentially leading to unnecessary interventions.
Anjiang Zhao, Fan Zhong, Yankui Liu, Guixing Li   +3 more
wiley   +1 more source

A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas

Haematologica, 2020
Paolo Strati, Loretta J. Nastoupil, Richard E Davis, Luis E. Fayad, Nathan Fowler, Fredrick B. Hagemeister, Larry Kwak, Yasuhiro Oki, Michael Wang, Jason Westin, Charnelle E. Ruben, Emily T. Wesson, Richard Piekarz, Michelle A. Fanale, Hun Ju Lee   +14 more
doaj   +1 more source

The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma

Biomarker Research
Inhibitors of Bruton’s tyrosine kinase (BTKi) and chimeric antigen receptor T-cell (CAR-T) therapy targeting CD19 are paradigm-shifting advances in treating patients with aggressive mantle cell lymphoma (MCL).
Vivian Jiang, William Lee, Tianci Zhang, Alexa Jordan, Fangfang Yan, Qingsong Cai, Joseph McIntosh, Jovanny Vargas, Yang Liu, Michael Wang   +9 more
doaj   +1 more source

Effects of washing procedures on cell loss in different diagnostic flow cytometry sample types

Cytometry Part B: Clinical Cytometry, EarlyView.
Gunnhild Vatne Leirvik, Trude Westgård, Mona Høysæter Fenstad, Henning Sørensen Øfsteng, Toril Holien   +4 more
wiley   +1 more source

Old disease, new twist

Journal of Hospital Medicine, EarlyView.
Abstract An 81‐year‐old man with a history of high‐grade urothelial carcinoma of the bladder and ureter on treatment with atezolizumab and tiragolumab presented to the emergency department with 5 months of malaise, generalized weakness, and fatigue and 2 weeks of subjective fevers. One month prior to presentation, he received an empiric 9‐day course of
Hadi Roudsari, Gurpreet Dhaliwal, Anand D. Jagannath, Alan H. Baik, Sam Brondfield   +4 more
wiley   +1 more source